游离血红蛋白与结合珠蛋白在需VV ECMO治疗的ARDS危重成人急性肾损伤中的作用
该研究从1044例ARDS患者队列中筛选出273例在启动ECMO前测量了游离血红蛋白(CFH)和结合珠蛋白的患者,按CFH浓度分为低(<5 mg/dl)、中(5-14 mg/dl)、高(≥15 mg/dl)三组,评估其与KDIGO 3期急性肾损伤(AKI)的关联。结果显示154例(56.4%)在启动ECMO时已存在AKI,AKI发生率随CFH浓度升高而逐步增加并在15 mg/dl处达平台。与低CFH组相比,中、高CFH组AKI风险分别增加约3倍和5倍(校正OR分别为2.69和5.47)。在CFH升高的患者中,中CFH组结合珠蛋白>2.7 g/l、高CFH组>2.4 g/l被确定为保护免受CFH相关AKI的临床临界值。作者认为较高结合珠蛋白浓度可能具有保护作用,应作为未来研究主题。
要点
- 在需VV ECMO的ARDS患者中,启动ECMO时AKI发生率为56.4%(154/273)。
- 与CFH<5 mg/dl组相比,CFH 5-14 mg/dl组AKI校正OR为2.69(95%CI 1.25-5.95,P=0.012),CFH≥15 mg/dl组校正OR为5.47(95%CI 2.00-15.9,P=0.001)。
- AKI发生率随CFH浓度升高而逐步增加,在CFH 15 mg/dl处达到平台。
- 在CFH升高的患者中,中CFH组结合珠蛋白>2.7 g/l(敏感性89.5%,95%CI 83-96)、高CFH组>2.4 g/l(敏感性90.2%,95%CI 80-97)被确定为保护免受CFH相关AKI的临床临界值。
- 作者认为,在CFH升高的患者中较高的血浆结合珠蛋白浓度可能保护免受CFH相关AKI,应作为未来研究主题。
适用人群与场景
- 需VV ECMO治疗的ARDS危重成人患者,且在启动ECMO治疗前进行了CFH和结合珠蛋白测量。
诊断标准与关键阈值
- AKI诊断采用KDIGO分期,主要终点为KDIGO 3期AKI。
- CFH浓度分组:低<5 mg/dl,中5-14 mg/dl,高≥15 mg/dl。
- 临床临界值:中CFH组结合珠蛋白>2.7 g/l,高CFH组结合珠蛋白>2.4 g/l。
研究设计与关键结果
- 研究类型为队列研究,从1044例ARDS患者中筛选出273例符合纳入标准,其中154例(56.4%)在启动ECMO时存在AKI。
- AKI发生率随CFH浓度升高而逐步增加,在15 mg/dl处达到平台。
- 与低CFH组(<5 mg/dl)相比,中CFH组(5-14 mg/dl)AKI校正OR为2.69(95%CI 1.25-5.95,P=0.012),高CFH组(≥15 mg/dl)AKI校正OR为5.47(95%CI 2.00-15.9,P=0.001)。
- 在CFH升高的患者中,发生AKI的患者血浆结合珠蛋白水平低于未发生AKI的患者。
- 中CFH组结合珠蛋白>2.7 g/l保护免受CFH相关AKI的敏感性为89.5%(95%CI 83-96),高CFH组>2.4 g/l的敏感性为90.2%(95%CI 80-97)。
证据类型、等级与局限
- 证据类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在需VV ECMO的ARDS患者中,启动ECMO前血浆CFH升高(中、高浓度组)与AKI风险增加独立相关,提示可关注CFH水平以评估AKI风险。
- 作者认为,在CFH升高的患者中较高的血浆结合珠蛋白浓度可能保护免受CFH相关AKI,应作为未来研究主题。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Increased plasma concentrations of circulating cell-free hemoglobin (CFH) are supposed to contribute to the multifactorial etiology of acute kidney injury (AKI) in critically ill patients while the CFH-scavenger haptoglobin might play a protective role. We evaluated the association of CFH and haptoglobin with AKI in patients with an acute respiratory distress syndrome (ARDS) requiring therapy with VV ECMO.
METHODS: Patients with CFH and haptoglobin measurements before initiation of ECMO therapy were identified from a cohort of 1044 ARDS patients and grouped into three CFH concentration groups using a risk stratification. The primary objective was to assess the association of CFH and haptoglobin with KDIGO stage 3 AKI. Further objectives included the identification of a target haptoglobin concentration to protect from CFH-associated AKI.
MEASUREMENTS AND MAIN RESULTS: Two hundred seventy-three patients fulfilled the inclusion criteria. Of those, 154 patients (56.4%) had AKI at ECMO initiation. The incidence of AKI increased stepwise with increasing concentrations of CFH reaching a plateau at 15 mg/dl. Compared to patients with low [< 5 mg/dl] CFH concentrations, patients with moderate [5-14 mg/dl] and high [≥ 15 mg/dl] CFH concentrations had a three- and five-fold increased risk for AKI (adjusted odds ratio [OR] moderate vs. low, 2.69 [95% CI, 1.25-5.95], P = 0.012; and OR high vs. low, 5.47 [2.00-15.9], P = 0.001). Among patients with increased CFH concentrations, haptoglobin plasma levels were lower in patients with AKI compared to patients without AKI. A haptoglobin concentration greater than 2.7 g/l in the moderate and 2.4 g/l in the high CFH group was identified as clinical cutoff value to protect from CFH-associated AKI (sensitivity 89.5% [95% CI, 83-96] and 90.2% [80-97], respectively).
CONCLUSIONS: In critically ill patients with ARDS requiring therapy with VV ECMO, an increased plasma concentration of CFH was identified as independent risk factor for AKI. Among patients with increased CFH concentrations, higher plasma haptoglobin concentrations might protect from CFH-associated AKI and should be subject of future research.
参考来源
- Graw JA, Hildebrandt P, Krannich A, et al. The role of cell-free hemoglobin and haptoglobin in acute kidney injury in critically ill adults with ARDS and therapy with VV ECMO. Crit Care. 2022. PMID: 35193645. doi:10.1186/s13054-022-03894-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。